CEO, Co-Founder, & Board Director
Paul Laur co-founded Spartina Biotechnologies in 2015. His previous companies include Eldorado Biofuels, in which he built a prototype algae to biofuels facility as PI in the National Alliance of Advanced Biofuels and Bioproducts, and Santa Fe Cider Company. Paul was Director of Operations at Anguilla Rums, and Director of Corporate Development at Pebble Labs where he brought in over $4 million dollars in Economic Development funding.
Paul holds a USCG Master Mariner’s license and a Master’s Degree from St. John’s College. He currently serves on the Boards of the NM Biotechnology and Biomedical Association and Ponderous Panda Capital Corporation.
Keara Sauber began her first business in financial services as a registered advisor in college. She spent five years with GlaxoSmithKline, in a prestigious leadership program prior to becoming an operating partner for a sleep lab where she managed physicians, sales, risk mitigation, planning, and facility needs. After selling the business, she was hired to a private equity firm where she led the acquisitions team to complete more than 23 asset purchase agreements. Keara was recruited to a VP position with a specialty lender backed by Goldman Sachs. She and her syndicate platform have originated more than $500 million dollars to date.
Keara holds dual Bachelor of Science degrees from Seton Hall University in Marketing with a minor in finance and a Bachelor of Science in Management with a minor in psychology.
Tanya Vinogradova Shah, Ph.D.
Dr. Vinogradova Shah is co-inventor of Siren technology. An expert in molecular biology, molecular cloning, genetics, and bacterial genome editing. She also has expertise in RNAi applications for gene silencing in bacteria, invertebrates, plants and mammalian cell cultures. Tatiana is author of 12 scientific papers and 7 patents (issued and pending).
Wataru Nishima, Ph.D.
Dr. Wataru has investigated biological systems including T4 phage infection, multi-drug resistance, Ebola/Zika virus transition, cytokine/ enzyme design, mRNA-tRNA translocation, using statistical/sequence analysis, and computational protein design. He also developed methodologies to characterize protein/glycan conformational changes.
Alexandre V. Pertzev, Ph.D.
Dr. Pertzev has diverse experience in nucleic-protein, protein-protein and enzyme-ligand interactions, regulation of gene expression and cell function, protein structure and function, evolution transfer and prevalence of genes, DNA and RNA modifying proteins and protein engineering. He also has expertise include microbiology, immunology, and molecular and cell biology.
Todd Buck, PhD.
Mintz | Patent Counsel
Dr. Buck is a seasoned patent prosecutor and portfolio manager for Mintz. His practice includes portfolio strategies, preparing and prosecuting patent applications & licensing transactions. He represents pharma and biotech clients in IP & FDA laws.
Scientific Advisory Board
Richard Sayre, Ph.D.
Inventor & Consultant
Dr. Sayre is a molecular biologist and co- inventor of Siren technology. He was voted one of the world’s most influential scientists by Nature Magazine. Dr. Sayre is also Sr. Research Scientist at the New Mexico Consortium and President of Richard Sayre Consulting.
Stephen Hedrick, Ph.D.
Dr. Hedrick is a molecular biologist with a wealth of experience in the field of immunology and a unique insight into the understanding of how immune systems in organisms evolve in concert with pathogens. His research work focuses on the regulation of the immune system including cell death, signal transduction, and evolution.
Jack Lewin, MD
Dr. Lewin is Chairman of the National Coalition on Health and CEO of Convergent Health Systems, a leading provider of advanced risk-mitigation strategies related to the Covid-19 pandemic. He has advised two Presidents of the United States on health care and public policy.
Robert Malone, MD, MS
Dr. Malone is a specialist in medical affairs as well as regulatory affairs. This includes writing, developing, reviewing and managing vaccine, bio-threat and biologics clinical trials and clinical development strategies. He has been involved in developing, designing, and providing oversight of approximately 40 phase 1 clinical trials , 20 phase 2 and 5 phase 3 clinical trials.
Board of Directors
Founder and President of Mountain Vector Energy, Albuquerque, NM
Dr. Steven Buelow
Executive Director of the New Mexico Consortium, Los Alamos, NM